Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.40 |
| ▸ | P2RY10 | O00398 | 8/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15412 | 0.98 | TSHR (0.55) | TSHRTHRBPOLBAPEX1HTT | |
| Ammonia Solution, Strong SCHEMBL18140963 | 0.96 | TSHR (0.53) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL345781 | 0.95 | TSHR (0.59) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL15881 | 0.93 | TSHR (0.62) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL15172 | 0.93 | TSHR (0.62) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL3447377 | 0.93 | TSHR (0.62) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL346466 | 0.93 | TSHR (0.62) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL3447994 | 0.93 | TSHR (0.62) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL16142 | 0.93 | TSHR (0.62) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL7073886 | 0.93 | TSHR (0.62) | TSHRTHRBPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105814092-B | Composition for hydrophilic cured product | 三井化学株式会社 | 2018-09-21 | — | — | CN | disclosed |